Maximising the potential of AKT inhibitors as anti-cancer treatments.
MetadataShow full item record
PI3K/AKT signalling is commonly disrupted in human cancers, with AKT being a central component of the pathway, influencing multiple processes that are directly involved in tumourigenesis. Targeting AKT is therefore a highly attractive anti-cancer strategy with multiple AKT inhibitors now in various stages of clinical development. In this review, we summarise the role and regulation of AKT signalling in normal cellular physiology. We highlight the mechanisms by which AKT signalling can be hyperactivated in cancers and discuss the past, present and future clinical strategies for AKT inhibition in oncology.
Version of record
Medicine (Banerji Drug Evaluation PD Group)
Medicine Drug Development Unit (de Bono)
License start date
Pharmacol Ther, 2017, 172 pp. 101 - 115